Hydroxyapatite Nanoparticles as a Novel Gene Carrier

Zhu, Shaihong; Huang, Baiyun; Zhou, Kechao; Huang, Shen; Liu, F.; Li, Y.M.; Xue, Zhigang; Long, Zhigao

doi:10.1023/b:nano.0000034721.06473.23

Cited by 108 publications

(56 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results were consistent with reports that the transfection efficiency of HAP nanoparticles can reach as high as approximately 50-80% of that of liposome-mediated transfection. 10 In addition, our study showed that HAP alone could also exert antitumour effects: HAP carrying si-scramble could inhibit cancer growth compared to the control; this was consistent with the study of Zhu et al, in which HAP alone could inhibit the in vitro proliferation of hepatocellular carcinoma cells. 10 Thus, the antitumour effects of HAP nanoparticles may be further enhanced when combined with Stat3-specific siRNA.…”

Section: Discussionsupporting

confidence: 91%

“…5 Compared to viral vectors, which possess risks of pathogenicity and immunogenicity, synthetic HAP nanoparticles have favourable biocompatibility and high osteoconductivity and/or osteoinductivity without immunogenicity or proinflammatory features. [6][7][8][9] HAP can not only directly inhibit the proliferation of cancer cells, 10 but also be used in a gene delivery system due to its safety, economy and efficiency. 11 Our previous study showed that Stat3-specific siRNA can markedly suppress Stat3 expression and inhibit the growth of prostate cancer cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo

Zhu¹,

Guo²,

Li³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

DNA vector-based Stat3-specific RNA interference (si-Stat3) blocks Stat3 signalling and inhibits prostate tumour growth. However, the antitumour activity depends on the efficient delivery of si-Stat3. The effects on the growth of mouse prostate cancer cells of si-Stat3 delivered by hydroxyapatite were determined in this study. RM-1 tumour blocks were transplanted into C57BL/6 mice. CaCl 2 -modified hydroxyapatite carrying si-Stat3 plasmids were injected into tumours, and tumour growth and histology were determined. The expression levels of Stat3, pTyr-Stat3, Bcl-2, Bax, Caspase3, VEGF and cyclin D1 were measured by western blot analysis. Amounts of apoptosis in cancer cells were analysed with immunohistochemistry and the terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labelling (TUNEL) assay. The results showed that hydroxyapatite-delivered si-Stat3 significantly suppressed tumour growth up to 74% (P,0.01). Stat3 expression was dramatically downregulated in the tumours. The immunohistochemistry and TUNEL results showed that si-Stat3-induced apoptosis (up to 42%, P,0.01). The Stat3 downstream genes Bcl-2, VEGF and cyclin D1 were also strongly downregulated in the tumour tissues that also displayed significant increases in Bax expression and Caspase3 activity. These results suggest that hydroxyapatite can be used for the in vivo delivery of plasmid-based siRNAs into tumours.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo

Zhu¹,

Guo²,

Li³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…8 In the last few years interactions between HAp and DNA are believed to play an important role in different fields, including the biomedical one. 9,10 For example, recent spectroscopic studies showed the contribution of vibrational modes of DNA, phospholipids and protein appears in HAp microcalcifications formed in the organism. 9 More recently, HAp nanoparticles (NPs) have been used as non-viral gene carriers.…”

Section: Introductionmentioning

confidence: 99%

Mineralization of DNA into nanoparticles of hydroxyapatite

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This a�sor�tion of carrier [11] 11] ] cou�� ob�ious�y re�uce first b�oo�-me�icine concentration of 5-FU�� an� reach to a re�axation effect�� it was a�so re�orte� in the a�so re�orte� in the re�orte� in the �iterature that Nano HA� cou�� ro�uce a com��ex with b�oo� serum �rotein in bio�ogica� bo�y [12��13] �� it was inferre� that the Nano HA�-5-FU �rotein com�oun� cou�� be forme� in anima� b�oo� after mixing of Nano HA� with 5-FU�� therefore not on�y the �oisonous by-effect of high concentration free 5-FU in bo�y cou�� be re�uce�� but centration free 5-FU in bo�y cou�� be re�uce�� but tration free 5-FU in bo�y cou�� be re�uce�� but a�so the b�oo� so�ubi�ity of Nano HA� cou�� be increase�.…”

Section: Discussionmentioning

confidence: 98%

Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX₂ tumor in rabbits by intravenous injection

Hu¹,

Liu²,

Tang³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To evaluate the effect of hydroxyapatite nanoparticles (Nano HAP) by intravenous injection on the inhibition of implanted hepatic VX2 tumor growth in rabbits and cell p53/c-Myc protein expression. METHODS:60 hepatic VX2 tumor-bearing rabbits was randomly divided into five groups. Nano HAP collosol 20 mg/kg, 40 mg/kg, 5-FU solutions 20 mg/mL, mixed liquor of 5-FU solution 20 mg/mL and Nano HAP collosol 20 mg/kg were infused by vein, normal saline conducted as the control. The general state, weight, liver function and gross tumor volume were detected dynamically. The expression of p53 and c-Myc gene protein in tumor tissue was detected by immunohistochemistry methods. RESULTS:The growth of implanted hepatic VX2 tumors was significantly inhibited in all therapy groups, 3 wk after the injection, the tumor control rates in Nano HAP collosol groups were 25.5% and 32.5% respectively, and the gross tumor volumes were obviously less than that of control group. (24.81 ± 5.17 and 22.73 ± 4.23 vs 33.32 ± 5.26, P < 0.05). The tumor control rate of 5-FU group was 43.7% (18.74 ± 4.40 vs 33.32 ± 5.26, P < 0.05), but the general state of the animals after injection aggravated; and the adverse reaction in the drug combination group obviously decreased. Due to the effect of Nano HAP, the positive expression of tumor associated the mutated p53 and c-Myc in tumor tissue was decreased obviously compared with the control group.CONCLUSION: Nano HAP has evident inhibitory action on rabbit implanted hepatic VX2 tumor in vivo , which may be the result of decreasing the expression of the mutated p53 and c-myc, and drug combination can obviously decrease the adverse reaction of 5-FU.

show abstract

Hydroxyapatite Nanoparticles as a Novel Gene Carrier

Cited by 108 publications

References 9 publications

Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo

Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo

Mineralization of DNA into nanoparticles of hydroxyapatite

Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX₂ tumor in rabbits by intravenous injection

Contact Info

Product

Resources

About

Hydroxyapatite Nanoparticles as a Novel Gene Carrier

Cited by 108 publications

References 9 publications

Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo

Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo

Mineralization of DNA into nanoparticles of hydroxyapatite

Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX2 tumor in rabbits by intravenous injection

Contact Info

Product

Resources

About

Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX₂ tumor in rabbits by intravenous injection